Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts Sells 5,415 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 5,415 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $8.11, for a total transaction of $43,915.65. Following the completion of the sale, the chief financial officer now owns 310,481 shares of the company’s stock, valued at approximately $2,518,000.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Austin Aerts also recently made the following trade(s):

• On Wednesday, May 8th, Austin Aerts sold 6,592 shares of Sera Prognostics stock. The stock was sold at an average price of $9.59, for a total transaction of $63,217.28.
• On Tuesday, March 26th, Austin Aerts sold 8,092 shares of Sera Prognostics stock. The stock was sold at an average price of $9.37, for a total transaction of $75,822.04.

Sera Prognostics Trading Up 3.1 %

NASDAQ:SERA traded up $0.25 during mid-day trading on Tuesday, hitting $8.33. The company’s stock had a trading volume of 97,907 shares, compared to its average volume of 199,040. Sera Prognostics, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $12.35. The company has a market capitalization of $271.97 million, a price-to-earnings ratio of -7.78 and a beta of 1.18. The stock has a fifty day moving average of $9.42 and a 200-day moving average of $7.89.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Sera Prognostics had a negative return on equity of 46.35% and a negative net margin of 11,843.79%. On average, equities analysts anticipate that Sera Prognostics, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, William Blair reissued an “outperform” rating on shares of Sera Prognostics in a research report on Friday, May 10th.

Institutional Trading of Sera Prognostics

Hedge funds have recently modified their holdings of the company. StepStone Group LP acquired a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $61,000. Sanders Morris Harris LLC acquired a new stake in shares of Sera Prognostics during the first quarter worth approximately $174,000. CWM LLC acquired a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $242,000. Resource Consulting Group Inc. acquired a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $265,000. Finally, Vanderbilt University acquired a new stake in shares of Sera Prognostics during the fourth quarter worth approximately $284,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.